Alzheimer’s disease and cytokine IL-10 gene polymorphisms: is there an association?

ABSTRACT Alzheimer’s disease (AD) is the most common form of dementia. In the last 15 years, a new theory has proposed the autoimmune mechanism as a trigger for AD. Studies on the association between AD and inflammatory biomarkers have yielded controversial results. Interleukin-10 (IL-10), an anti-inflammatory mediator, has been pointed out as one of the main cytokines associated with the occurrence of AD. Moreover, treatment that increases IL-10 levels could be a potential therapy for AD, since this cytokine acts on amyloid and pro-inflammatory molecule reduction. Based on the current literature, this study reviews evidence regarding the role of IL-10 polymorphisms in the context of AD, which has been shown to be of paramount importance for attenuating neuroinflammation, cognitive dysfunction and neurodegeneration.

[1]  K. Gomes,et al.  Polymorphisms in cytokine genes influence cognitive and functional performance in a population aged 75 years and above , 2017, International journal of geriatric psychiatry.

[2]  J. Fragoso,et al.  Association of interleukin-10 polymorphisms with risk factors of Alzheimer's disease and other dementias (SADEM study). , 2016, Immunology letters.

[3]  Weiming Xia,et al.  Genomics of Alzheimer Disease: A Review. , 2016, JAMA neurology.

[4]  Xinwen Zhou,et al.  The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ , 2016, Translational Neurodegeneration.

[5]  A. Verkhratsky,et al.  Astroglia dynamics in ageing and Alzheimer's disease. , 2016, Current opinion in pharmacology.

[6]  M. Lynch,et al.  Linking T cells to Alzheimer's disease: from neurodegeneration to neurorepair. , 2016, Current opinion in pharmacology (Print).

[7]  M. Kamal,et al.  Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines. , 2016, Current pharmaceutical design.

[8]  J. Choi,et al.  Genetic polymorphisms of interleukin genes and the risk of Alzheimer's disease: An update meta-analysis , 2016, Meta gene.

[9]  D. Wilcock,et al.  Neuroinflammation in Alzheimer’s disease; A source of heterogeneity and target for personalized therapy , 2015, Neuroscience.

[10]  T. Rème,et al.  Central Nervous System and Peripheral Inflammatory Processes in Alzheimer’s Disease: Biomarker Profiling Approach , 2015, Front. Neurol..

[11]  J. Leszek,et al.  The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy. , 2015, Current pharmaceutical design.

[12]  L. Steardo,et al.  Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes , 2015, Front. Neurosci..

[13]  I. Lombardo,et al.  The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study , 2015, Alzheimer's & Dementia.

[14]  Burkhard Becher,et al.  Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.

[15]  O. Hanon,et al.  There is no correlation between peripheral inflammation and cognitive status at diagnosis in Alzheimer’s disease , 2015, Aging Clinical and Experimental Research.

[16]  James A. Eddy,et al.  IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior , 2015, Neuron.

[17]  M. Guillot-Sestier,et al.  Il10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology , 2015, Neuron.

[18]  A. Cianciulli,et al.  IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells. , 2015, International immunopharmacology.

[19]  Sung-Wan Kim,et al.  Associations of cytokine genes with Alzheimer's disease and depression in an elderly Korean population , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  B. Baune,et al.  Inflammasomes in neuroinflammation and changes in brain function: a focused review , 2014, Front. Neurosci..

[21]  SangYun Kim,et al.  Characterization of inflammatory biomarkers and candidates for diagnosis of Alzheimer’s disease , 2014, BioChip Journal.

[22]  Ozlem Keskin,et al.  The structural network of Interleukin-10 and its implications in inflammation and cancer , 2014, BMC Genomics.

[23]  E. Camargos,et al.  Cytokine Gene Polymorphisms and Alzheimer's Disease in Brazil , 2013, Neuroimmunomodulation.

[24]  J. Ávila,et al.  Role of Neuroinflammation in Adult Neurogenesis and Alzheimer Disease: Therapeutic Approaches , 2013, Mediators of inflammation.

[25]  G. Ricevuti,et al.  Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly. , 2011, Autoimmunity reviews.

[26]  D. Swaab,et al.  Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease , 2011, Neurobiology of Aging.

[27]  T. Kiyota,et al.  AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice , 2011, Gene Therapy.

[28]  E. Génin,et al.  No replication of genetic association between candidate polymorphisms and Alzheimer's disease , 2011, Neurobiology of Aging.

[29]  J Zhang,et al.  The −1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer's disease: A meta-analysis , 2011, Journal of the Neurological Sciences.

[30]  S. Rivest,et al.  The role of microglial cell subsets in Alzheimer's disease. , 2011, Current Alzheimer research.

[31]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Alzheimer's Disease , 2010, Biological Psychiatry.

[32]  R. Sabat.  IL-10 family of cytokines. , 2010, Cytokine & growth factor reviews.

[33]  G. Annoni,et al.  Intereleukin-10 Promoter Polymorphism in Mild Cognitive Impairment and in Its Clinical Evolution , 2010, International journal of Alzheimer's disease.

[34]  M. Megna,et al.  Cytokine polymorphisms and Alzheimer disease: possible associations , 2010, Neurological Sciences.

[35]  H. Gurvit,et al.  The combinations of TNFα–308 and IL‐6 –174 or IL‐10 –1082 genes polymorphisms suggest an association with susceptibility to sporadic late‐onset Alzheimer’s disease , 2009, Acta neurologica Scandinavica.

[36]  Rodney W. Johnson,et al.  Cognitive deficits in interleukin-10-deficient mice after peripheral injection of lipopolysaccharide , 2009, Brain, Behavior, and Immunity.

[37]  G. Maestre,et al.  Prevalence of dementia in Latin America: a collaborative study of population-based cohorts , 2009, International Psychogeriatrics.

[38]  S. Sorbi,et al.  Association of IL10 promoter polymorphism in Italian Alzheimer's disease , 2007, Neuroscience Letters.

[39]  S. Love,et al.  Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's disease , 2006, Neuroscience Letters.

[40]  B. Bergamasco,et al.  Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients , 2006, Neurological Sciences.

[41]  V. W. Henderson,et al.  Estrogen-containing hormone therapy and Alzheimer’s disease risk: Understanding discrepant inferences from observational and experimental research , 2006, Neuroscience.

[42]  H. Chiu,et al.  The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease , 2005, Neurobiology of Aging.

[43]  G. Annoni,et al.  Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer’s disease , 2004, Neurobiology of Aging.

[44]  G. Binetti,et al.  Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease , 2004, Neuroscience Letters.

[45]  A. Kurz,et al.  Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease , 2003, Neuroscience Letters.

[46]  C. Franceschi,et al.  Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease , 2003, Genes and Immunity.

[47]  T. Mosmann,et al.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones , 1989, The Journal of experimental medicine.

[48]  R. DuBois,et al.  The Jeremiah Metzger Lecture: Inflammation, Immune Modulators, and Chronic Disease. , 2015, Transactions of the American Clinical and Climatological Association.

[49]  N. Herrmann,et al.  Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. , 2015, Journal of Alzheimer's disease : JAD.

[50]  K. Gomes,et al.  TGF-β1 Codon 10 T>C Polymorphism Influences Short-Term Functional and Cognitive Decline in Healthy Oldest-Old Individuals: The Pietà Study. , 2015, Journal of Alzheimer's disease : JAD.

[51]  C. Caruso,et al.  Association between interleukin-10 polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. , 2012, Journal of Alzheimer's disease : JAD.

[52]  D. Swaab,et al.  Estrogen receptor alpha and its splice variants in the hippocampus in aging and Alzheimer's disease. , 2007, Neurobiology of aging.

[53]  G. Schellenberg,et al.  Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. , 2006, Archives of neurology.

[54]  B. Bergamasco,et al.  Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. , 2006, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[55]  Mario Cortina-Borja,et al.  Open Access Journal of Neuroinflammation Replication by the Epistasis Project of the Interaction between the Genes for Il-6 and Il-10 in the Risk of Alzheimer's Disease , 2022 .

[56]  Tumor Necrosis Factor (cid:1) and Interleukin 10 Promoter Region Polymorphisms and Risk of Late-Onset Alzheimer Disease , 2022 .